Healthcare Dec 04, 2021 09:31 AM (GMT+8) · EqualOcean
On December 3, 2021, Fuhong Hanlin announced that the company independently developed bevacizumab injection hanbetai ® The application for listing registration has been approved by the State Drug Administration (nmpa) for the treatment of: 1) metastatic colorectal cancer; 2) Advanced, metastatic or recurrent non-small cell lung cancer. Han Beitai ® It is the fourth approved product of the company. Previously, rituximab hanlikang ®、 Trastuzumab hantrayou ® (EU trade name: zercepac) ®) And adalimumab, handayuan ® It has been successfully listed, covering blood tumors, solid tumors, autoimmune diseases and other fields